162 related articles for article (PubMed ID: 37786437)
21. Mutational analysis of renal angiomyolipoma associated with tuberous sclerosis complex and the outcome of short-term everolimus therapy.
Ni J; Yan F; Qin W; Yu L; Zhang G; Liu F; Yang X; Yang B; Hao C; Wang T; Liu P; Yuan J; Wu G
Sci Rep; 2019 Oct; 9(1):14337. PubMed ID: 31586081
[TBL] [Abstract][Full Text] [Related]
22. Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide.
Davies M; Saxena A; Kingswood JC
Orphanet J Rare Dis; 2017 Feb; 12(1):35. PubMed ID: 28202028
[TBL] [Abstract][Full Text] [Related]
23. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S
Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
[TBL] [Abstract][Full Text] [Related]
24. Safety and Effectiveness of Medical Therapy and Surgical Intervention for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex.
Wang Z; Zhang W; Fan Y; Zhang X
Cancer Control; 2022; 29():10732748221140266. PubMed ID: 36471546
[TBL] [Abstract][Full Text] [Related]
25. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.
Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Frost M; Belousova E; Sauter M; Nonomura N; Brakemeier S; de Vries PJ; Berkowitz N; Miao S; Segal S; Peyrard S; Budde K
Nephrol Dial Transplant; 2016 Jan; 31(1):111-9. PubMed ID: 26156073
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Whittemore VH; Thiele EA; Ford JP; Shah G; Cauwel H; Lebwohl D; Sahmoud T; Jozwiak S
Lancet; 2013 Jan; 381(9861):125-32. PubMed ID: 23158522
[TBL] [Abstract][Full Text] [Related]
27. Everolimus versus sirolimus for angiomyolipoma associated with tuberous sclerosis complex: a multi-institutional retrospective study in China.
Luo C; Zhang YS; Zhang MX; Chen MF; Li Y; Qi L; Li HZ; Zu XB; Cai Y
Orphanet J Rare Dis; 2021 Jul; 16(1):299. PubMed ID: 34217357
[TBL] [Abstract][Full Text] [Related]
28. Everolimus Treatment for an Early Infantile Subependymal Giant Cell Astrocytoma With Tuberous Sclerosis Complex.
Fukumura S; Watanabe T; Takayama R; Minagawa K; Tsutsumi H
J Child Neurol; 2015 Aug; 30(9):1192-5. PubMed ID: 25143481
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis.
Budde K; Zonnenberg BA; Frost M; Cheung W; Urva S; Brechenmacher T; Stein K; Chen D; Kingswood JC; Bissler JJ
Br J Clin Pharmacol; 2016 May; 81(5):958-70. PubMed ID: 26580489
[TBL] [Abstract][Full Text] [Related]
30. Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Curran MP
Paediatr Drugs; 2012 Feb; 14(1):51-60. PubMed ID: 22136276
[TBL] [Abstract][Full Text] [Related]
31. Everolimus for the treatment of subependymal giant cell astrocytoma probably causing seizure aggravation in a child with tuberous sclerosis complex: a case report.
Wiemer-Kruel A; Woerle H; Strobl K; Bast T
Neuropediatrics; 2014 Apr; 45(2):129-31. PubMed ID: 24293099
[TBL] [Abstract][Full Text] [Related]
32. Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening.
Trelinska J; Dachowska I; Kotulska K; Fendler W; Jozwiak S; Mlynarski W
Anticancer Drugs; 2015 Apr; 26(4):437-42. PubMed ID: 25719621
[TBL] [Abstract][Full Text] [Related]
33. Effects of everolimus on tuberous sclerosis complex-associated renal angiomyolipoma: A preliminary report.
Tsai JD; Wei CC; Yang SH; Fan HC; Hsu CC; Tung MC; Tsai ML; Sheu JN
Nephrology (Carlton); 2017 Dec; 22(12):1017-1022. PubMed ID: 27565896
[TBL] [Abstract][Full Text] [Related]
34. Continuous low-dose everolimus shrinkage tuberous sclerosis complex-associated renal angiomyolipoma: a 48-month follow-up study.
Wei CC; Tsai JD; Sheu JN; Chen SL; Tsao TF; Yang SH; Tsai JD
J Investig Med; 2019 Mar; 67(3):686-690. PubMed ID: 30455224
[TBL] [Abstract][Full Text] [Related]
35. Renal angiomyolipoma and tuberous sclerosis complex: long-term safety and efficacy outcomes of Everolimus therapy.
Ruiz Guerrero E; Ledo Cepero MJ; Ojeda Claro AV; Soto Delgado M; Álvarez-Ossorio Fernández JL
Actas Urol Esp (Engl Ed); 2021 May; 45(4):264-272. PubMed ID: 33637375
[TBL] [Abstract][Full Text] [Related]
36. [HUGE RENAL ANGIOMYOLIPOMA (AML) IN TUBEROUS SCLEROSIS COMPLEX (TSC) WHICH IS CONTROLED BY EVEROLIMUS: A CASE REPORT].
Kanbara T; Sakaeda K; Kusaka N; Akebi N
Nihon Hinyokika Gakkai Zasshi; 2016; 107(1):54-58. PubMed ID: 28132993
[TBL] [Abstract][Full Text] [Related]
37. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex.
Wang W; Guo H; Shi B; Sun H; Li H; Zhang Y; Cai Y
Int Urol Nephrol; 2019 Apr; 51(4):671-676. PubMed ID: 30756282
[TBL] [Abstract][Full Text] [Related]
38. Dramatic relapse of seizures after everolimus withdrawal.
Mingarelli A; Vignoli A; La Briola F; Peron A; Giordano L; Banderali G; Canevini MP
Eur J Paediatr Neurol; 2018 Jan; 22(1):203-206. PubMed ID: 28888335
[TBL] [Abstract][Full Text] [Related]
39. Safety of Everolimus in Patients Younger than 3 Years of Age: Results from EXIST-1, a Randomized, Controlled Clinical Trial.
Jóźwiak S; Kotulska K; Berkowitz N; Brechenmacher T; Franz DN
J Pediatr; 2016 May; 172():151-155.e1. PubMed ID: 26858193
[TBL] [Abstract][Full Text] [Related]
40. The association between computed tomography attenuation value of renal angiomyolipoma associated with tuberous sclerosis complex and response to everolimus.
Liao Z; Li J; Zhao Y; Wang Z; Wang X; Qiu D; Zhang Y
World J Urol; 2024 Jan; 42(1):10. PubMed ID: 38183428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
